Dihydroartemisinin–piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia

Gianluca Russo, Mariangela L’Episcopia, Michela Menegon, Samaly Santos Souza, Bruna Ghyslaine Djeunang Dongho, Vincenzo Vullo, Naomi W. Lucchi, Carlo Severini

Research output: Contribution to journalArticlepeer-review

Abstract

Dihydroartemisinin–piperaquine (DHA–PPQ) is the artemisinin combination therapy that was recently introduced for the treatment of Plasmodium falciparum uncomplicated malaria, but emerging resistance in South-East Asia is threatening its use. This report describes a case of DHA–PPQ treatment failure in uncomplicated malaria occurring in an immigrant living in Italy, after a travel to Ethiopia. Thirty days after malaria recovery following DHA–PPQ therapy, the patient had malaria recrudescence. According to the genotyping analysis, the same P. falciparum was responsible for both episodes. Thus, it seems important to consider possible malaria recrudescence occurring after DHA–PPQ therapy in patients from African countries

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalInfection
DOIs
Publication statusAccepted/In press - Jul 6 2018

Keywords

  • Dihydroartemisinin
  • Ethiopia
  • Failure
  • Malaria recrudescence
  • Piperaquine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Dihydroartemisinin–piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia'. Together they form a unique fingerprint.

Cite this